ArticleArthritis & rheumatology (Hoboken, N.J.)2020
Interleukin-17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin-25-Driven Intestinal Inflammation.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Characterization of the Oral and Gut Microbiota in Patients with Psoriatic Diseases: A Systematic Review.Acta dermato-venereologica · 2021Pooled it
- The Effectiveness and Safety of Probiotic Supplements for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Preclinical Trials.Journal of immunology research · 2021Pooled it
- Mechanistic insights into how gut homeostasis and immune-system crosstalk shape ankylosing spondylitis.Frontiers in immunology · 2026Review
- Gut microbiota and ankylosing spondylitis: mechanisms, functional pathways, and research trends.Frontiers in microbiology · 2026Article
- Rapamycin treatment ameliorates HLA-B27-mediated gut inflammation and alters the microbiome in experimental spondyloarthritis.Frontiers in immunology · 2026Article
- Gut Microbiome Correlations in Hidradenitis Suppurativa Patients.Journal of clinical medicine · 2025Article
- Review
- Pharmacomicrobiomics in inflammatory skin diseases: past, present, and the future.Frontiers in microbiology · 2025Review
- Study of the Gut Microbiome in Patients with Psoriatic Arthritis.European journal of rheumatology · 2024Article
- The effect of anti-TNF drugs on the intestinal microbiota in patients with spondyloarthritis, rheumatoid arthritis, and inflammatory bowel diseases.Rheumatology and immunology research · 2024Review
- Gut epithelial Interleukin-17 receptor A signaling can modulate distant tumors growth through microbial regulation.Cancer cell · 2024Article
- Investigating causal associations among gut microbiota, metabolites, and psoriatic arthritis: a Mendelian randomization study.Frontiers in microbiology · 2024Article
- Unraveling the microbiome-metabolome nexus: a comprehensive study protocol for personalized management of Behçet's disease using explainable artificial intelligence.Frontiers in microbiology · 2024Article
- Innate-like T Cells: Connecting the Dots Linking Microscopic Intestinal Inflammation to Spondyloarthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2023Article
- Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies.Nature reviews. Rheumatology · 2023Review
- Successful secukinumab therapy in plaque psoriasis is associated with altered gut microbiota and related functional changes.Frontiers in microbiology · 2023Article
- The Yin-Yang Pharmacomicrobiomics on Treatment Response in Inflammatory Arthritides: A Narrative Review.Genes · 2022Review
- Article
- An integrative study of the microbiome gut-brain-axis and hippocampal inflammation in psychosis: Persistent effects from mode of birth.Schizophrenia research · 2022Article
- Gut Microbiota in Psoriasis.Nutrients · 2022Review
Corrections and comments
- Commented on by
Authors and funding
21 authors at 7 institutions in 3 countries.
Funding
Abstract
objectiveTo characterize the ecological effects of biologic therapies on the gut bacterial and fungal microbiome in psoriatic arthritis (PsA)/spondyloarthritis (SpA) patients.
methodsFecal samples from PsA/SpA patients pre- and posttreatment with tumor necrosis factor inhibitors (TNFi; n = 15) or an anti-interleukin-17A monoclonal antibody inhibitor (IL-17i; n = 14) underwent sequencing (16S ribosomal RNA, internal transcribed spacer and shotgun metagenomics) and computational microbiome analysis. Fecal levels of fatty acid metabolites and cytokines/proteins implicated in PsA/SpA pathogenesis or intestinal inflammation were correlated with sequence data. Additionally, ileal biopsies obtained from SpA patients who developed clinically overt Crohn's disease (CD) after treatment with IL-17i (n = 5) were analyzed for expression of IL-23/Th17-related cytokines, IL-25/IL-17E-producing cells, and type 2 innate lymphoid cells (ILC2s).
resultsThere were significant shifts in abundance of specific taxa after treatment with IL-17i compared to TNFi, particularly Clostridiales (P = 0.016) and Candida albicans (P = 0.041). These subclinical alterations correlated with changes in bacterial community co-occurrence, metabolic pathways, IL-23/Th17-related cytokines, and various fatty acids. Ileal biopsies showed that clinically overt CD was associated with expansion of IL-25/IL-17E-producing tuft cells and ILC2s (P < 0.05), compared to pre-IL-17i treatment levels.
conclusionIn a subgroup of SpA patients, the initiation of IL-17A blockade correlated with features of subclinical gut inflammation and intestinal dysbiosis of certain bacterial and fungal taxa, most notably C albicans. Further, IL-17i-related CD was associated with overexpression of IL-25/IL-17E-producing tuft cells and ILC2s. These results may help to explain the potential link between inhibition of a specific IL-17 pathway and the (sub)clinical gut inflammation observed in SpA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.